Payment overview · 2025
General Payments
$254.10
14 reported records · 10 companies
Healthcare provider profile · identity verified
Tammy L Brown, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBANY, KY · NPI 1609845882
Verified facts
What the public records show
CMS Open Payments records show Tammy L Brown, MD received $254.10 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.10 | 23.6% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.87 | 15.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.01 | 15.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.01 | 8.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.58 | 7.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.94 | 7.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.14 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.62 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.94 | 5.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.89 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.10 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.10 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 173 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 635 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 80 |
| Furosemide | Furosemide | 481 | 83 |
| Omeprazole | Omeprazole | 428 | 62 |
| Gabapentin | Gabapentin | 411 | 61 |
| Losartan Potassium | Losartan Potassium | 398 | 72 |
| Potassium Chloride | Potassium Chloride | 369 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 339 | 55 |
| Lisinopril | Lisinopril | 321 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 303 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 43 |
| Carvedilol | Carvedilol | 249 | 42 |
| Metformin Hcl | Metformin Hcl | 237 | 45 |
| Alprazolam | Alprazolam | 225 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 51 |
| Montelukast Sodium | Montelukast Sodium | 218 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 211 | 42 |
| Sertraline Hcl | Sertraline Hcl | 200 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 193 | 33 |
| Jardiance | Empagliflozin | 192 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 190 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 39 |
| Eliquis | Apixaban | 173 | 23 |
| Glimepiride | Glimepiride | 173 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 52 |
| Atenolol | Atenolol | 169 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 30 |
| Meloxicam | Meloxicam | 167 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 27 |
| Prednisone | Prednisone | 148 | 98 |
| Ropinirole Hcl | Ropinirole Hcl | 144 | 22 |
| Azithromycin | Azithromycin | 136 | 105 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 131 | 35 |
| Simvastatin | Simvastatin | 129 | 26 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 124 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 116 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 19 |
| Mirtazapine | Mirtazapine | 114 | 18 |
| Famotidine | Famotidine | 112 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 112 | 20 |
| Allopurinol | Allopurinol | 111 | 19 |
| Meclizine Hcl | Meclizine Hcl | 105 | 30 |
| Mounjaro | Tirzepatide | 93 | 13 |
| Trazodone Hcl | Trazodone Hcl | 91 | 14 |
| Celecoxib | Celecoxib | 90 | 18 |
| Ibuprofen | Ibuprofen | 89 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 86 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 16 |
| Fluconazole | Fluconazole | 84 | 36 |
| Trulicity | Dulaglutide | 83 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 79 | 17 |
| Amoxicillin | Amoxicillin | 78 | 47 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 77 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 16 |
| Ozempic | Semaglutide | 75 | 14 |
| Cephalexin | Cephalexin | 73 | 36 |
| Linzess | Linaclotide | 73 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 13 |
| Pregabalin | Pregabalin | 71 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 70 | 52 |
| Risperidone | Risperidone | 70 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 21 |
| Lorazepam | Lorazepam | 69 | 14 |
| Donepezil Hcl | Donepezil Hcl | 67 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 27 |
| Tramadol Hcl | Tramadol Hcl | 66 | 18 |
| Buspirone Hcl | Buspirone Hcl | 65 | 14 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Naproxen | Naproxen | 63 | 12 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 61 | suppressed |
| Entresto | Sacubitril/Valsartan | 60 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 38 |
| Ezetimibe | Ezetimibe | 59 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 39 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 51 | 31 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Metolazone | Metolazone | 47 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 11 |
| Spironolactone | Spironolactone | 44 | 13 |
| Diazepam | Diazepam | 43 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 17 |
| Cefdinir | Cefdinir | 42 | 37 |
| Lacosamide | Lacosamide | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Topiramate | Topiramate | 40 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Metronidazole | Metronidazole | 39 | 24 |
| Promethazine Hcl | Promethazine Hcl | 39 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Temazepam | Temazepam | 37 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 35 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 19 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Ibu | Ibuprofen | 29 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 29 | 27 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 12 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 24 | suppressed |
| Nystatin | Nystatin | 23 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dexilant | Dexlansoprazole | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.10 · 14 records | PFIZER INC. | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, MOUNJARO, NURTEC ODT, REXULTI, VRAYLAR, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error